Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis indicate improved efficacy in refractory cGvHD, suggesting further treatment exploration.
Belumosudil demonstrates promising efficacy and a favorable safety profile in refractory cGvHD. Our findings support further investigation in earlier treatment and disease course.
No takes yet. Share an insight, caveat, or question.
Rathje et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: